Carl Dambkowski, who serves as a director at Oruka Therapeutics, Inc. (NASDAQ:ORKA), reported the disposition of common stock valued at roughly $6.19 million on May 21, 2026. The transaction involved the sale of 104,000 shares of the company's common equity.
The timing of these sales is notable, occurring after the stock had achieved a substantial 424% return over the previous year. Despite this strong performance, some valuation analyses suggest that the current market pricing may exceed its fair value according to InvestingPro's analysis.
Mr. Dambkowski executed the divestiture through multiple separate transactions. The sale prices ranged between $57.71 and $60.31 per share, which were relatively close to the prevailing trading price of $60.61 at the time. Crucially, these sales were structured under a Rule 10b5-1 trading plan that Mr. Dambkowski had initially established on February 19, 2026.
Prior to the recent divestment, Mr. Dambkowski had accumulated an additional holding of Oruka Therapeutics common stock. Specifically, he acquired a total of 62,260 shares through the exercise of options and warrants. These specific shares were obtained at varied prices, ranging from $6.84 to $11.77 per share, amounting to a total cost of approximately $494,804.
Following the reported sales, Mr. Dambkowski's direct holdings in Oruka Therapeutics common stock stand at 73,743 shares.
The company has also been involved in several significant financial maneuvers recently. Oruka Therapeutics announced an upsized public offering designed to sell 9,660,000 shares of common stock at a price of $72.50 per share, which is expected to generate gross proceeds of approximately $700.4 million.
Furthermore, the company launched a separate $500 million stock offering. This particular offering includes both common stock and pre-funded warrants, and it contains a 30-day option allowing underwriters the possibility of purchasing an additional $75 million worth of common stock. These large financial activities follow positive interim results reported from Oruka’s EVERLAST-A Phase 2a trial concerning ORKA-001, which is being developed as a treatment for moderate-to-severe plaque psoriasis.
The clinical trial demonstrated encouraging outcomes, noting that 63.5% of the participants achieved a PASI 100 score by Week 16. In response to these developments, two financial institutions adjusted their outlook: H.C. Wainwright increased its price target for Oruka Therapeutics to $120 while maintaining a Buy rating. Concurrently, Clear Street raised its price target to $131, also sustaining a Buy rating. These cumulative events underscore growing confidence in both the therapeutic advancements and the financial strategy of Oruka.
Risks
- <p><strong>Valuation Concerns:</strong> Despite strong performance, the stock is noted by one source as potentially overvalued when measured against its fair value analysis.</p>
- <p><strong>High Capital Expenditure/Dilution:</strong> The company is undergoing multiple large-scale public offerings ($700.4 million and $500 million), which represent substantial capital raises but also carry implications regarding potential shareholder dilution.</p>
More from Insider Trading
Risks
- <p><strong>Valuation Concerns:</strong> Despite strong performance, the stock is noted by one source as potentially overvalued when measured against its fair value analysis.</p>
- <p><strong>High Capital Expenditure/Dilution:</strong> The company is undergoing multiple large-scale public offerings ($700.4 million and $500 million), which represent substantial capital raises but also carry implications regarding potential shareholder dilution.</p>